EVERY Company Secures Funding to Boost US Protein Manufacturing

Significant Investment in Domestic Protein Production

The EVERY Company, a pioneer in producing innovative protein ingredients, has recently received a remarkable $2 million grant from the US Department of Defense. This funding is specifically aimed at assessing the feasibility of establishing a manufacturing site within the US, a significant step towards boosting domestic biomanufacturing capabilities.

Exploring New Horizons in Protein Innovation

The financial support will facilitate a thorough evaluation of manufacturing sites for EVERY’s two primary proteins. These proteins include a highly soluble formulation focused on boosting protein content in various foods and ovalbumin, which serves as a functional substitute for traditional egg and egg whites, currently protected by a foundational patent.

Contributing to National Security Initiatives

This grant is part of the Distributed Bioindustrial Manufacturing Program initiated by the DoD, which underscores the importance of enhancing US biomanufacturing in critical sectors: fabrication, firepower, fitness, food, and fuel. Arturo Elizondo, the CEO of EVERY, emphasized the potential of this investment to solidify domestic supply chains, reduce dependency on imports, and position the United States as a frontrunner in food technology amidst the challenges posed by food insecurity and climate change.

Military Applications of Advanced Proteins

In alignment with the funding's objectives, EVERY intends to develop military applications for its proprietary proteins. One notable application involves utilizing its soluble protein to create high-quality nutritional solutions presented in compact formats. The technology behind this protein allows it to yield impressive results, such as a protein-enriched drink that has the appearance and flavor of plain water while delivering substantial protein nutrition.

Expanding Production Capacity

EVERY has consistently demonstrated its production process at an industrial scale over 100,000 liters, successfully obtaining FDA approval for all products. With ambitions to enter the mass market over the next year, Elizondo noted that many client demands require vast quantities of protein. The funding from the Department of Defense will significantly aid in ramping up production capacities to satisfy these growing requirements.

Environmental Benefits and Economic Contributions

Beyond the direct impact on protein production, EVERY’s methodology significantly conserves land and water resources compared to conventional protein production methods. By leveraging US-grown corn as the primary feedstock, EVERY also actively supports local rural economies, reinforcing the positive cycle of local agricultural health and sustainability.

Recent Innovations and Partnerships

This achievement follows a recent announcement in which EVERY secured a pioneering patent for ovalbumin, broadening its application spectrum. Additionally, EVERY has forged partnerships with global brands, enhancing its portfolio and market reach. Collaborative agreements with influential companies such as Grupo Nutresa, Colombia’s foremost food enterprise, and Grupo Palacios, recognized worldwide for producing Spanish omelets, demonstrate EVERY's expansive industry connections.

Another notable collaboration includes the Unilever brand, the Vegetarian Butcher, which further highlights EVERY's innovative approaches and market adaptability.

About EVERY™

EVERY™ is a cutting-edge food technology enterprise based in San Francisco. Their mission revolves around establishing a more secure and accessible global food system, providing food and beverage companies with bio-identical protein ingredients crafted through precision fermentation. Among the innovative ingredients offered are OvoPro™ and OvoBoost™, both of which are FDA-approved and cater to a wide array of food applications, enhancing nutritional value across multiple markets.

Frequently Asked Questions

What is the purpose of the $2M grant awarded to EVERY?

The grant is aimed at assessing the feasibility of establishing a US-based manufacturing facility for EVERY's protein products.

What proteins are being developed by EVERY?

EVERY is focusing on a highly soluble protein for food fortification and ovalbumin, which replaces traditional egg ingredients.

How does this funding relate to national security?

The funding is part of a program aimed at enhancing domestic biomanufacturing, reducing reliance on foreign imports, and ensuring food security.

What unique applications does EVERY’s protein technology offer?

The technology allows for high-quality nutrient delivery in formats that are convenient and appealing, such as protein-enriched beverages.

What are the environmental advantages of EVERY's production methods?

EVERY’s process uses significantly less land and water than conventional protein production, while supporting local agricultural economies.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.